VolitionRx Q2 2026: H1 revenue up 112% to $1.4M, operating loss down 34%

VOLITIONRX LTD

H1 2026 revenue $1.4M, up 112% YoY; Q2 revenue ~$0.4M, flat YoY.
Q2 operating loss $4.2M, down 34% YoY; operating expenses down 32%.
Net cash used in ops $5.2M in Q2, down 18% YoY; raised $5.3M from equity sales.
In talks with 12+ diagnostic/liquid biopsy firms for licensing; Sysmex collaboration announced.
Nu.Q Vet feline assay manuscript submitted; publication could unlock $5M milestone.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.